Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) subsidiary's Amikacin Sulfate Injection passes generic drug consistency evaluation.

Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) announced that recently, its controlling subsidiary Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (referred to as "Tianxin Pharmaceutical") received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration, and Amikacin Sulfate Injection (2ml:0.2g) (200,000 units) has passed the generic drug quality and efficacy consistency evaluation. Amikacin Sulfate Injection is indicated for serious infections caused by sensitive Gram-negative bacilli such as Pseudomonas aeruginosa and other Pseudomonas species, Escherichia coli, Proteus species, Klebsiella species, Enterobacter species, Serratia species, Acinetobacter species, and Staphylococcus species (methicillin-susceptible strains), including bacteremia or septicemia, bacterial endocarditis, lower respiratory tract infections, bone and joint infections, biliary tract infections, intra-abdominal infections, complicated urinary tract infections, and skin and soft tissue infections. As this product is stable against most aminoglycoside-modifying enzymes, it is particularly suitable for the treatment of serious infections caused by Gram-negative bacilli strains resistant to kanamycin, gentamicin, or tobramycin.